Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s lead therapeutic programs includes Treg-enhancing biologics (COYA 300 Series product
Company profile
Ticker
COYA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
COYA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEF 14A
Definitive proxy
28 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
19 Mar 24
8-K
Other Events
19 Jan 24
424B3
Prospectus supplement
16 Jan 24
EFFECT
Notice of effectiveness
16 Jan 24
CORRESP
Correspondence with SEC
10 Jan 24
UPLOAD
Letter from SEC
9 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.89 mm | 10.89 mm | 10.89 mm | 10.89 mm | 10.89 mm | 10.89 mm |
Cash burn (monthly) | 738.70 k | (no burn) | 1.19 mm | 976.84 k | (no burn) | 320.27 k |
Cash used (since last report) | 4.93 mm | n/a | 7.94 mm | 6.53 mm | n/a | 2.14 mm |
Cash remaining | 5.95 mm | n/a | 2.95 mm | 4.36 mm | n/a | 8.75 mm |
Runway (months of cash) | 8.1 | n/a | 2.5 | 4.5 | n/a | 27.3 |
Institutional ownership, Q2 2023
19.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 10 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 5.26 bn |
Total shares | 2.85 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Howard Berman | 939.34 k | $4.37 mm |
AIGH Capital Management | 586.87 k | $2.39 bn |
Hirschman Orin | 560.00 k | $2.56 mm |
Greenlight Capital | 392.65 k | $1.60 bn |
Worth Venture Partners | 146.49 k | $596.23 mm |
CM Management | 60.00 k | $244.00 k |
Geode Capital Management | 58.57 k | $238.39 mm |
BAC Bank Of America | 46.05 k | $187.43 mm |
UBS UBS Group AG - Registered Shares | 26.60 k | $108.27 mm |
Mirador Capital Partners | 15.36 k | $62.52 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jan 24 | Snyder David S | Stock Option Common Stock | Grant | Acquire A | No | No | 5.9 | 81,819 | 482.73 k | 81,819 |
31 Jan 24 | Fred Grossman | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 5.9 | 74,069 | 437.01 k | 74,069 |
31 Jan 24 | Fred Grossman | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 5.9 | 81,819 | 482.73 k | 81,819 |
31 Jan 24 | Howard Berman | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 5.9 | 189,680 | 1.12 mm | 189,680 |
2 Jan 24 | Ross Wilbur L JR | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 6.97 | 10,000 | 69.70 k | 10,000 |
1 Jan 24 | Anabella Villalobos | Stock Option Common Stock, par value $0.0001 per share | Grant | Acquire A | No | No | 7.41 | 5,000 | 37.05 k | 5,000 |
News
Chardan Capital Maintains Buy on Coya Therapeutics, Raises Price Target to $14
20 Mar 24
Coya Therapeutics FY23 EPS $(0.79) Vs $(4.73) YoY; Collaboration Revenue Of $6M
19 Mar 24
Coya Therapeutics To Present Data On Immune System And Regulatory T Cell Contributions In Frontotemporal Dementia Patients At AD/PD 2024 Conference
29 Feb 24
Coya Therapeutics To Present Novel Biomarker Survival Data In Large Cohort Of ALS Patients At Society Of Neuroimmune Pharmacology Conference
22 Feb 24
Coya Therapeutics Issues Letter To Stockholders Highlighting Expansion Of COYA 302 Into Alzheimer's Disease And Coya's Pathway To A "Pipeline In A Product"
21 Feb 24
Press releases
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
18 Apr 24
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
8 Apr 24
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
19 Mar 24
Thinking about buying stock in Vale SA, Virpax Pharmaceuticals, Paymentus, Futu Holdings, or Coya Therapeutics?
13 Mar 24
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
12 Mar 24